Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Venetoclax is a new type of anticancer drug, a Bcl-2 inhibitor developed by the American pharmaceutical company AbbVie, which is effective against cancer and produces less than current drugs. The side effects of this study were mainly done by researchers in the United States and Australia, and the results of the research were published in the international journal Nature Medicine.

Indication: CLL(Chronic Lymphocytic Leukemia)

All the products under the patent are only for R&D use.

Patent from AbbVie, expiry date(The U.S):Jun.27, 2031.